Clinical trial / 2020
Nicotinamide riboside supplementation for 12 weeks did not alter skeletal muscle mitochondrial respiration, content, or morphology in obese, insulin-resistant men.
In a randomized, placebo-controlled trial, 40 middle-aged, obese, insulin-resistant men received 1000 mg nicotinamide riboside (NR) or placebo twice daily for 12 weeks. NR supplementation decreased NAMPT protein levels in skeletal muscle by 14%, but steady-state NAD+ levels and other biosynthetic enzymes were unchanged. NR did not affect skeletal muscle mitochondrial respiratory capacity, mitochondrial-associated protein abundance, mitochondrial fractional area, or network morphology.
- Study type
- Randomized, placebo-controlled clinical trial
- Who was studied
- 40 middle-aged, obese, insulin-resistant men
- What was measured
- Skeletal muscle mitochondrial respiration, content, morphology, and NAD+ metabolites
THE PAPER
Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men.
Dollerup OL, Chubanava S, Agerholm M, Søndergård SD, Altıntaş A, Møller AB, Høyer KF, Ringgaard S, Stødkilde-Jørgensen H, Lavery GG, Barrès R, Larsen S, Prats C, Jessen N, Treebak JT. J Physiol, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.